Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Malignant Melanoma

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 47 articles:
HTML format
Text format



Single Articles


    December 2019
  1. POKLEPOVIC AS, Luke JJ
    Considering adjuvant therapy for stage II melanoma.
    Cancer. 2019 Dec 23. doi: 10.1002/cncr.32585.
    PubMed     Text format     Abstract available


    November 2019
  2. ZHANG H, Zhu H, Deng G, Zito CR, et al
    PLEKHA5 regulates tumor growth in metastatic melanoma.
    Cancer. 2019 Nov 26. doi: 10.1002/cncr.32611.
    PubMed     Text format     Abstract available


  3. COHEN JV, Wang N, Venur VA, Hadfield MJ, et al
    Neurologic complications of melanoma.
    Cancer. 2019 Nov 14. doi: 10.1002/cncr.32619.
    PubMed     Text format     Abstract available


  4. ABUDU B, Cook KA, Gershenwald JE, Cohen PR, et al
    Quantitative associations between health insurance and stage of melanoma at diagnosis among nonelderly adults in the United States.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32587.
    PubMed     Text format     Abstract available


    October 2019
  5. HOLBROOK K, Lutzky J, Davies MA, Davis JM, et al
    Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
    Cancer. 2019 Oct 28. doi: 10.1002/cncr.32547.
    PubMed     Text format     Abstract available


  6. KANDEL M, Dalle S, Bardet A, Allayous C, et al
    Quality-of-life assessment in French patients with metastatic melanoma in real life.
    Cancer. 2019 Oct 22. doi: 10.1002/cncr.32554.
    PubMed     Text format     Abstract available


  7. PIRES DA SILVA I, Lo S, Quek C, Gonzalez M, et al
    Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy.
    Cancer. 2019 Oct 4. doi: 10.1002/cncr.32522.
    PubMed     Text format     Abstract available


  8. BARTLETT EK, Flynn JR, Panageas KS, Ferraro RA, et al
    High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy.
    Cancer. 2019 Oct 4. doi: 10.1002/cncr.32506.
    PubMed     Text format     Abstract available


    August 2019
  9. SCHVARTSMAN G, Ma J, Bassett RL Jr, Haydu LE, et al
    Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
    Cancer. 2019 Aug 9. doi: 10.1002/cncr.32454.
    PubMed     Text format     Abstract available



  10. Erratum: Jeter JM, Bowles TL, Curiel-Lewandrowski C, et al. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019:125:18-44.
    Cancer. 2019;125:2706.
    PubMed     Text format    


    July 2019
  11. RULLI E, Legramandi L, Salvati L, Mandala M, et al
    The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis.
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32375.
    PubMed     Text format     Abstract available


    May 2019
  12. NAJJAR YG, Puligandla M, Lee SJ, Kirkwood JM, et al
    An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.
    Cancer. 2019 May 8. doi: 10.1002/cncr.32162.
    PubMed     Text format     Abstract available


    March 2019
  13. KOFF JL, Waller EK
    Improving cancer-specific outcomes in solid organ transplant recipients: Where to begin?
    Cancer. 2019;125:838-842.
    PubMed     Text format     Abstract available


    January 2019
  14. GIBNEY GT, Atkins MB
    Choice of first-line therapy in metastatic melanoma.
    Cancer. 2019 Jan 29. doi: 10.1002/cncr.31774.
    PubMed     Text format    


  15. OTT PA, Pavlick AC, Johnson DB, Hart LL, et al
    A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
    Cancer. 2019 Jan 28. doi: 10.1002/cncr.31892.
    PubMed     Text format     Abstract available


    December 2018
  16. APPENZELLER S, Gesierich A, Thiem A, Hufnagel A, et al
    The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31843.
    PubMed     Text format     Abstract available


  17. SAAB KR, Mooradian MJ, Wang DY, Chon J, et al
    Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31889.
    PubMed     Text format     Abstract available


    November 2018
  18. BHATTY M, Kato S, Piha-Paul SA, Naing A, et al
    Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies.
    Cancer. 2018 Nov 1. doi: 10.1002/cncr.31812.
    PubMed     Text format     Abstract available


    October 2018

  19. Older melanoma patients may respond better to anti-PD1 immunotherapy.
    Cancer. 2018;124:3961.
    PubMed     Text format    


  20. TARHINI AA, Frankel P, Ruel C, Ernstoff MS, et al
    NCI 8628: a randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.
    Cancer. 2018 Oct 10. doi: 10.1002/cncr.31734.
    PubMed     Text format     Abstract available


  21. JETER JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, et al
    Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials.
    Cancer. 2018 Oct 3. doi: 10.1002/cncr.31719.
    PubMed     Text format     Abstract available


    September 2018
  22. GOLDSTEIN AM, Stidd KC, Yang XR, Fraser MC, et al
    Pediatric Melanoma in Melanoma-Prone Families.
    Cancer. 2018 Sep 12. doi: 10.1002/cncr.31641.
    PubMed     Text format     Abstract available


    July 2018
  23. FAJE AT, Lawrence D, Flaherty K, Freedman C, et al
    High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.
    Cancer. 2018 Jul 5. doi: 10.1002/cncr.31629.
    PubMed     Text format     Abstract available


    April 2018
  24. DAVIS EJ, Johnson DB, Sosman JA, Chandra S, et al
    Melanoma: What do all the mutations mean?
    Cancer. 2018 Apr 17. doi: 10.1002/cncr.31345.
    PubMed     Text format     Abstract available


    March 2018
  25. TSAI KK, Bollin KB, Patel SP
    Obstacles to improving outcomes in the treatment of uveal melanoma.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31284.
    PubMed     Text format     Abstract available


  26. PRINTZ C
    First person: Antoni Ribas, MD, PhD: The physician-scientist from the University of California at Los Angeles researches how new therapies for patients with advanced malignant melanoma can help to overcome resistance to treatment.
    Cancer. 2018;124:1097-1098.
    PubMed     Text format    


  27. LEHRER S, Rheinstein PH, Rosenzweig KE
    Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.
    Cancer. 2018 Mar 15. doi: 10.1002/cncr.31262.
    PubMed     Text format    


  28. SLOOT S, Chen YA, Zhao X, Weber JL, et al
    Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.
    Cancer. 2018 Mar 15. doi: 10.1002/cncr.31261.
    PubMed     Text format    


    October 2017
  29. MCWILLIAMS RR, Allred JB, Slostad JA, Katipamula R, et al
    NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab +/- everolimus for metastatic melanoma.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31072.
    PubMed     Text format     Abstract available


  30. AMIT M, Tam S, Abdelmeguid AS, Roberts DB, et al
    Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31083.
    PubMed     Text format     Abstract available


  31. SLOOT S, Chen YA, Zhao X, Weber JL, et al
    Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
    Cancer. 2017 Oct 12. doi: 10.1002/cncr.30946.
    PubMed     Text format     Abstract available


    September 2017
  32. BENCI JL, Minn AJ, Vachani CC, Bach C, et al
    Survivorship care planning in skin cancer: An unbiased statistical approach to identifying patterns of care-plan use.
    Cancer. 2017 Sep 8. doi: 10.1002/cncr.30985.
    PubMed     Text format     Abstract available


    August 2017
  33. ROBIN TP, Jones BL, Gordon OM, Phan A, et al
    A comprehensive comparative analysis of treatment modalities for sinonasal malignancies.
    Cancer. 2017;123:3040-3049.
    PubMed     Text format     Abstract available


    June 2017
  34. SZCZEPANIAK SLOANE RA, Gopalakrishnan V, Reddy SM, Zhang X, et al
    Interaction of molecular alterations with immune response in melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  35. BYRNE EH, Fisher DE
    Immune and molecular correlates in melanoma treated with immune checkpoint blockade.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  36. WESTPHAL D, Glitza Oliva IC, Niessner H
    Molecular insights into melanoma brain metastases.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  37. LIM SY, Menzies AM, Rizos H
    Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  38. PEREZ-GUIJARRO E, Day CP, Merlino G, Zaidi MR, et al
    Genetically engineered mouse models of melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  39. REDDY BY, Miller DM, Tsao H
    Somatic driver mutations in melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  40. BARUCH EN, Berg AL, Besser MJ, Schachter J, et al
    Adoptive T cell therapy: An overview of obstacles and opportunities.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  41. JOHNSON DB, Sullivan RJ, Menzies AM
    Immune checkpoint inhibitors in challenging populations.
    Cancer. 2017;123:1904-1911.
    PubMed     Text format     Abstract available


    May 2017
  42. SHIELD PW, Frost F, Finnimore JL, Wright RG, et al
    External quality assurance in nongynecologic cytology: The Australasian experience.
    Cancer. 2017;125:349-361.
    PubMed     Text format     Abstract available


    March 2017
  43. KALINSKY K, Lee S, Rubin KM, Lawrence DP, et al
    A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
    Cancer. 2017 Mar 23. doi: 10.1002/cncr.30663.
    PubMed     Text format     Abstract available


    February 2017

  44. Some Europeans with melanoma lack access to new, lifesaving drugs.
    Cancer. 2017;123:543-544.
    PubMed     Text format    


    December 2016
  45. HOU JY, Baptiste C, Hombalegowda RB, Tergas AI, et al
    Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.
    Cancer. 2016 Dec 27. doi: 10.1002/cncr.30473.
    PubMed     Text format     Abstract available


  46. KIM DW, Haydu LE, Joon AY, Bassett RL Jr, et al
    Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.
    Cancer. 2016 Dec 2. doi: 10.1002/cncr.30463.
    PubMed     Text format     Abstract available


    October 2016
  47. CLARKE LE, Flake DD 2nd, Busam K, Cockerell C, et al
    An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi.
    Cancer. 2016 Oct 21. doi: 10.1002/cncr.30385.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: